Bayer's Chart Test and Legal Calendar Converge on a Pivotal September Session

Bayer shares hover near 50-day average as September 14 glyphosate settlement hearing looms; strong Q2 results and debt reduction offer support.

The next fortnight will tell Bayer shareholders whether the stock's recent retreat is a pause or a pivot. The shares slipped 1.9 percent to €47.50 on Friday, leaving them 12 percent below the 52-week high of €53.86 — and, more tellingly, just 1.5 percent above the 50-day moving average of €46.78.

That line in the sand now doubles as the market's proxy for the broader legal overhang. With the glyphosate settlement hearing rescheduled to September 14 — pushed back from August 19 after both sides requested more time to process opt-out requests following the US Supreme Court's Durnell ruling — traders are weighing chart support against a calendar that could either clear the air or reopen old wounds.

The Technical Crossroads

The 50-day average has become the immediate battleground. A decisive break below €46.78 would flash a warning signal, potentially opening the door to a test of the 100-day average at €42.43. The relative strength index sits at 47.8, squarely in neutral territory, offering little directional bias. The stock has already slipped beneath a short-term trendline, a sign that buying momentum is cooling even as the broader uptrend — reinforced by a 28 percent gain since January and a 70 percent advance over twelve months — remains intact above the 200-day average.

The market is pricing in turbulence either way. Annualized volatility of 25 percent suggests meaningful swings are possible if the September 14 hearing disappoints or slips again.

The Balance-Sheet Tailwind

Operationally, the picture has brightened considerably. Bayer's second-quarter results, published just over a week ago, showed group revenue of €10.87 billion and adjusted EBITDA of €2.14 billion, comfortably ahead of analyst consensus. Crop Science benefited from firmer glyphosate prices and the EPA's reauthorization of dicamba herbicides.

The company has also made tangible progress on leverage. Following the sale of a minority stake in its contraception business, Bayer trimmed its year-end net financial debt forecast to €29–30 billion, a target reinforced by the €3 billion Apollo deal. The combination of debt reduction and a resilient agriculture division has been the structural driver behind the stock's recovery.

The Opt-Out Calculus

The September 14 hearing is now the fulcrum. At stake is the February settlement worth up to $7.25 billion, payable over as many as 21 years, designed to resolve a substantial portion of the glyphosate litigation. The Supreme Court's 7–2 decision in June — finding that the federal FIFRA statute preempts stricter state warning requirements — weakened the foundation of many jury verdicts against Monsanto, a favorable development for Bayer.

But that same ruling has altered the calculus for plaintiffs. The opt-out window it opened means claimants must now decide whether to stay in the settlement or pursue individual cases. A surge in withdrawals could force renegotiation or yet another postponement, leaving the litigation overhang unresolved and new legal costs difficult to quantify.

Divergent Analyst Views

The Street is split on how this plays out. Goldman Sachs raised its price target to €63.50 on August 5 with a "Buy" rating, while UBS and DZ Bank followed with targets of €62 and €60 respectively — calls grounded in the strong quarterly numbers and the more favorable legal landscape. JPMorgan, by contrast, reaffirmed "Overweight" but held its target at a notably more conservative €50, signaling greater caution on the residual litigation risk.

The stock's RSI of 53.3 and 30-day annualized volatility of 24 percent suggest the market has not yet picked a side. The shares closed at €48.44 on the day the postponement was announced, down 1.6 percent — a muted reaction that leaves room for a decisive move once the hearing date arrives.

For now, the trade is defined by two reference points: whether €46.78 holds on the chart, and how many plaintiffs choose to walk away from the settlement table. The September 14 hearing will answer both questions at once.